Centre Hospitalier Intercommunal Compiegne Noyon — Clinical Trial Site

17 Registered trials

10 Currently recruiting

Organisation

Centre Hospitalier Intercommunal Compiegne Noyon

Location

Compiegne, France

Identifier

ORG-100044185

Address

8 Avenue Henri Adnot, 60200, France

Departments

#3332:Cardiology
2403: Cardiology
3332, Cardiology
Anesthésie-réanimation
Cardiology
Department Oncology
hematology
hépato gastro enterology
Onco-hematology
oncologie
Oncology
Pneumologie
Pneumology
Service d’Hématologie
Service Hématologie

Clinical trials at this site (17)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Comparison of Landiolol versus standard of care for prevention of mortality in patients hospitalized for a septic shock with hypercontractli… Pending

2024-518251-31-00 patients hospitalized for a septic shock with hypercont 5
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Onco-hematology 5 2019-07-25
AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-labe… Recruiting

2023-506843-40-00 Mycobacterium xenopi pulmonary infection 5 2025-10-29
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p… Recruiting

2024-517325-43-00 multiple myeloma 4 2025-06-19
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Metastatic HER2-positive breast cancer 5 2024-12-03
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study Recruiting

2023-503481-23-00 Maintenance treatment in metastatic non-squamous lung c 5 2023-03-20
A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting

2024-515354-24-00 Low risk myelodysplastic syndrom without RS having fail 9 2022-05-18
CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co… Recruiting

2024-518578-15-00 Is to demonstrate a non inferior efficacy of azithromyc 5 2018-02-05
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23